For the past decade, venture capitalists have invested in companies that are developing new technologies to treat late-stage chronic obstructive pulmonary disorders such as emphysema, hoping to create a new line of devices to aid patients who can't draw enough oxygen from a single breath. ( See "Emphysema: Elusive Target for Device Companies," IN VIVO , December 2008 Also see "Emphysema: Elusive Target for Device Companies" - In Vivo, 1 December, 2008..) Despite hundreds of millions in venture capital dollars, the companies have made little progress in bringing these products to market in the US.
Pulmonary Device Companies Take It To The Streets - In Europe
For the past decade, venture capitalists have invested in companies that are developing new technologies to treat late-stage chronic obstructive pulmonary disorders.Despite hundreds of millions in venture capital dollars, the companies have made little progress in bringing these products to market in the US. But this band of start-ups is taking the fight to the streets - of Europe.
More from Europe
More from Geography
• By
Its move comes as the Swiss recognize the need to ensure adequate supplies on medical devices in its country.
• By
Back-to-back meetings at LSX? No time to attend the innovator showcase? Here is what you might have missed from medtech innovators at the LSX World Congress Europe on 29 April.
• By
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.